# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-13T17:58:23.561432

---

**Idea Fidelity**

The paper faithfully pursues the manifest’s core idea: it estimates the causal effect of staggered EPCS mandates on opioid mortality using the Callaway–Sant’Anna estimator and exploits the CDC VSRR provisional overdose data. The subtype decomposition—prescription opioids (T40.2) versus illicit opioids (T40.4, T40.1)—appears as the touted mechanism and placebo test. The paper also examines robustness across estimation methods, control groups, and sample windows, aligning with the manifest’s emphasis on credible identification in a multi-state setting. One minor omission is a more explicit discussion of the secondary SDUD prescribing data mentioned in the manifest; no results using Medicaid prescribing volumes are presented, so the paper stops short of linking the policy to the prescription channel via prescribing behavior. Including even limited analysis or a clearer explanation for the absence of the SDUD data would improve fidelity to the original proposal.

---

**Summary**

The paper evaluates whether state mandates requiring electronic prescribing for controlled substances affected opioid mortality between 2016 and 2024. Using a Callaway–Sant’Anna staggered DiD design with CDC provisional overdose death data, it finds no statistically significant effects on prescription opioid deaths (T40.2), synthetic opioid deaths (T40.4), heroin deaths, or total opioid deaths; placebo outcomes for cocaine and psychostimulants are also null. Robustness checks (Sun–Abraham, alternate control groups, excluding early adopters) support the conclusion that EPCS mandates did not move mortality meaningfully.

---

**Essential Points**

1. **Event Study Transparency and Parallel Trends:** Table 3 purports to show event-study coefficients, but the table is empty and no pre- or post-trend estimates are actually reported. Without plotted or tabulated pre-trends, it is difficult to assess the plausibility of the parallel-trends assumption that underpins the CS-DiD strategy. Please populate the event-study table (and preferably provide a figure) with the actual event-time coefficients, including the 95% confidence intervals, so readers can verify whether pre-treatment coefficients are near zero and whether the policy timing is exogenous.

2. **Mechanism Evidence Using Prescribing Data:** One of the paper’s central claims is that the mandates aim to constrain the prescription channel, yet there is no empirical evidence that prescribing behavior changed after the mandates. The manifest mentions SDUD Medicaid prescribing data for this purpose, but the paper lacks results (or explanation for their absence). Including regression evidence on prescribing volume, morphine milligram equivalents, or indicators of high-risk prescribing from SDUD (even for a subset of states) would substantiate that the policy had at least a measurable effect on the upstream channel; without it, the null on mortality may simply reflect zero first-stage. If data limitations prevent such analysis, explicitly state that and discuss implications for interpreting the null.

3. **Interpretation of Null Results Given Waning Power:** The paper interprets the null as evidence EPCS “fails to curb the crisis.” Yet the minimum detectable effect at 80% power is roughly 2.3 deaths per 100,000—about half the mean prescription opioid rate—and many confidence intervals remain wide. While the direction of the baseline estimate is positive (implying higher mortality), the Sun–Abraham estimate is negative, and the TWFE estimate is also negative though insignificant. This sign instability suggests that the data are not informative enough to decisively rule out a modestly beneficial effect. Please temper the interpretation accordingly: emphasize the limits of statistical power, explicitly report the point estimates’ heterogeneity across cohorts, and perhaps conduct a power analysis (or equivalently report bounds) that clarifies what effect sizes are confidently ruled out versus what remains plausible.

---

**Suggestions**

- **Populate Event Study and Graphical Diagnostics:** Beyond tabulated event-study coefficients, add a figure showing the dynamic treatment effects over time with confidence bands. It aids interpretation and is expected in empirical papers with staggered DiD. Include the number of states contributing to each event time (since later lags may have few treated units) and, if possible, overlay placebo event studies for synthetic opioid deaths to show differential dynamics.

- **Clarify Treatment Coding for Mid-Year Mandates:** The treatment coding assigns mid-year mandates (e.g., New York March 2016) to the full year, which introduces measurement error in exposure timing. Discuss the implications, and consider a sensitivity check where treatment begins in the year after activation or uses fractional exposure weights for partial-years. If precise implementation dates are available, an event-study that aligns relative time to the actual month (if data allow) would sharpen identification of short-run effects.

- **Address Potential Spillovers and Policy Bundling:** The narrative acknowledges co-occurring policies (PDMP enhancements, prescribing limits), but the current empirical strategy does not isolate EPCS effects from these bundles. Consider controlling for concurrent opioid policies (e.g., allowing for enactment dummies for PDMP interoperability or prescribing limits) or leveraging states that passed EPCS mandates without simultaneous reforms to see if results differ. Alternatively, emphasize that the subtype decomposition mitigates—but does not eliminate—concerns about bundled reforms because many co-policies still target prescription opioids; clarify this nuance.

- **Explore Heterogeneity by Crisis Timing or Adoption Cohort:** Since the crisis shifted toward illicit fentanyl over time, the effectiveness of EPCS might vary by the calendar period or cohort. Run cohort-specific ATTs or interact treatment with a “pre-2018 vs. post-2018” indicator to see if older cohorts (when prescription opioids were more prevalent) exhibit different patterns. Similarly, test whether outcomes differ between states that adopted the mandate before versus after the fentanyl wave gained dominance. Such heterogeneity analysis can enrich the policy discussion and address whether timing explains the null.

- **Report First-Stage Variation in EPCS Adoption or Compliance (if possible):** If data exist on the share of prescriptions actually transmitted electronically (before and after mandates) or enforcement/compliance rates, reporting them would help assess whether the mandates altered behavior. Even descriptive statistics showing a jump in EPCS usage in treated states relative to controls would strengthen the claim that the policy had “teeth.”

- **Discuss Alternative Outcomes and Longer Horizons:** Given that the crisis involves changing drug mixes, consider exploring other outcomes beyond mortality—such as emergency department visits, nonfatal overdoses, or prescription volumes (as noted). If these data are unavailable, mention that explicitly and suggest them for future research. Additionally, since the mandates' effect might materialize gradually (e.g., as providers adopt new systems), consider estimating distributed-lag models or cumulative exposure effects.

- **Clarify Standardized Effect Size Interpretation:** Table A.1 introduces standardized effect sizes but labels treatment effects like 0.1382 as “moderate positive,” which may confuse readers given the wide confidence intervals and null statistical significance. Clarify that these classifications reflect point estimates relative to the outcome standard deviation and do not imply statistically meaningful effects. Alternatively, present standardized effects alongside their confidence intervals to remind readers of uncertainty.

- **Improve Discussion of Policy Implications:** The concluding policy discussion is strong but could benefit from nuance—for instance, acknowledging that null mortality effects do not imply zero benefits (e.g., improved error reduction or administrative efficiency). Suggest complementary policies (harm reduction, treatment access) that could work in tandem with EPCS. This not only rounds out the narrative but also situates the work within a broader policy toolkit.

By addressing these issues—particularly the event study presentation, mechanism validation via prescribing data, and nuanced interpretation of the null—the paper will deliver a clearer and more compelling assessment of EPCS mandates’ role in the opioid crisis.
